Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Science Evolution At FDA ‘Transformative,’ Advisors Say

This article was originally published in The Gray Sheet

Executive Summary

An FDA Science Board subcommittee report finds industry and researcher perceptions of FDA's science readiness has improved over the past eight years. But the agency still faces major challenges tied to the current speed of scientific and technical progress.


Related Content

In Case You Missed It: Top 10 "Gray Sheet" Stories In September
FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?
Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
CDRH Can’t Rely On ‘Network of Experts’ Due To Confidentiality Concerns





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts